Filing Flows › Inhibrx Biosciences (INBX) › Next earnings date
Inhibrx Biosciences (INBX) earnings on Nov 13, 2026: what to expect
Inhibrx Biosciences (INBX) is expected to report earnings on Nov 13, 2026, in 5 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$2.35 (−$2.57 to −$2.14, 2 estimates), against −$2.28 a year ago. It beat the EPS estimate in 0% of the quarters on record; Filing Flows' model gives it a 39% chance of beating next time.
What to watch
Last quarter (Q2 2025) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$2.28, against the analysts' −$2.35.
The last report
Inhibrx Biosciences reported revenue of $1.3M for the second quarter 2025 (13× Y/Y), net loss $28.7M. How it makes money → · Every quarter →
Inhibrx Biosciences' latest quarter
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
When does INBX report earnings?
Inhibrx Biosciences is expected to report on Nov 13, 2026.
What are analysts expecting from Inhibrx Biosciences?
EPS of −$2.35 for the quarter.
Does Inhibrx Biosciences usually beat earnings?
It beat the consensus EPS estimate in 0% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.